# Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant

> **NCT02945150** · PHASE4 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 8 (actual)

## Conditions studied

- Renal Failure

## Interventions

- **DRUG:** elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination)

## Key facts

- **NCT ID:** NCT02945150
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-01
- **Primary completion:** 2019-08-20
- **Final completion:** 2020-03-05
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2020-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02945150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02945150, "Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02945150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*